TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Exclusion Criteria

• •1. Subject has received anti-CD38 monoclonal antibody treatment previously;
• •2. Subject has received CAR-T cell therapy previously;
• •3. Subject has previously received allogenic stem cell transplant, or subject has received autologous stem cell transplant within 3 months before administration of the study agent;
• •4. Primary refractory multiple myeloma (subject failed to generate any minimal response or any degree of response to any therapy);
• •5. Subject has received anti-myeloma treatment (radiotherapy is excluded) within 4 weeks or 5 PK half-lives of the treatment, whichever longer, before the first study agent administration.